Scilex Holding Company (SCLX)

1,9300 +0,1400 (+7,82%) Alla chiusura: 04:00PM EDT

Scilex Holding Company

960 San Antonio Road
Palo Alto, CA 94303
United States
650 516 4310
https://www.scilexholding.com

Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 106

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Henry H. Ji Ph.D.	Executive Chairman	885,43k	N/D	1964
Mr. Jaisim Shah	President, CEO & Director	971,52k	N/D	1960
Mr. Stephen Ma	Senior VP, CFO & Corporate Secretary	708,78k	N/D	1973
Dr. Suketu D. Desai Ph.D.	CTO & Senior VP	N/D	N/D	1966
Ms. Gigi DeGuzman	Executive Director of Administrative Operations & Head of Human Resources	N/D	N/D	N/D
Mr. Steven F. Lincoln J.D.	General Counsel & Chief Compliance Officer	N/D	N/D	N/D
Mr. Sumant Rajendran	Executive Director of Marketing	N/D	N/D	N/D
Mr. Mike Ciaffi	National Sales Director	N/D	N/D	N/D
Mr. Suresh K. Khemani	Senior VP & Chief Commercial Officer	456,82k	N/D	1960
Dr. Dmitri V. Lissin M.D.	Senior VP & Chief Medical Officer	528,83k	N/D	1959

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Governance aziendale

L'ISS Governance QualityScore di Scilex Holding Company al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.